139 related articles for article (PubMed ID: 8018956)
1. Sixteen week dose intense chemotherapy for inoperable, locally advanced breast cancer.
Armstrong DK; Fetting JH; Davidson NE; Gordon GB; Huelskamp AM; Abeloff MD
Breast Cancer Res Treat; 1993 Dec; 28(3):277-84. PubMed ID: 8018956
[TBL] [Abstract][Full Text] [Related]
2. Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancer.
Abeloff MD; Beveridge RA; Donehower RC; Fetting JH; Davidson NE; Gordon GG; Waterfield WC; Damron DJ
J Natl Cancer Inst; 1990 Apr; 82(7):570-4. PubMed ID: 2313733
[TBL] [Abstract][Full Text] [Related]
3. Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma.
Mikhak B; Zahurak M; Abeloff MD; Fetting JH; Davidson NE; Donehower RC; Waterfield W; Kennedy MJ
Cancer; 1999 Feb; 85(4):899-904. PubMed ID: 10091768
[TBL] [Abstract][Full Text] [Related]
4. Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma.
Ribas A; Albanell J; Solé-Calvo LA; Gallardo E; Bellmunt J; Vera R; Vidal R; Carulla J; Baselga J
Cancer; 1998 Mar; 82(5):878-85. PubMed ID: 9486577
[TBL] [Abstract][Full Text] [Related]
5. High-dose, brief duration, multiagent chemotherapy for metastatic breast cancer.
Lamar RE; Greco FA; Johnson DH; Murphy PB; Hainsworth JD
Cancer; 1994 Apr; 73(7):1842-8. PubMed ID: 8137208
[TBL] [Abstract][Full Text] [Related]
6. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
[TBL] [Abstract][Full Text] [Related]
7. Induction chemotherapy of dibromodulcitol, Adriamycin, vincristine, tamoxifen, and Halotestin with methotrexate in metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1181).
Chang AY; Putt M; Pandya KJ; Harris J; Gelman R; Tormey DC; Falkson G
Am J Clin Oncol; 1998 Feb; 21(1):99-104. PubMed ID: 9499270
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
9. Induction chemotherapy and intensification with autologous bone marrow reinfusion in patients with locally advanced and disseminated breast cancer.
Mulder NH; Mulder PO; Sleijfer DT; Willemse PH; van der Ploeg E; Dolsma WV; de Vries EG
Eur J Cancer; 1993; 29A(5):668-71. PubMed ID: 8471323
[TBL] [Abstract][Full Text] [Related]
10. Alternating chemotherapy regimens for patients with metastatic breast cancer. A pilot study based on tumor marker kinetics. Cancer and Leukemia Group B.
Kiang DT; Kennedy BJ; Younger J; Perry MC; Schilling A; Korzun AH; Nowak BS; Wood W
Cancer; 1995 Feb; 75(3):826-30. PubMed ID: 7828133
[TBL] [Abstract][Full Text] [Related]
11. Treatment of locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery.
Lippman ME; Sorace RA; Bagley CS; Danforth DW; Lichter A; Wesley MN
NCI Monogr; 1986; (1):153-9. PubMed ID: 3022156
[TBL] [Abstract][Full Text] [Related]
12. Results of treatment with high intensity, brief duration chemotherapy in poor prognosis non-Hodgkin's lymphoma.
McMaster ML; Greer JP; Wolff SN; Johnson DH; Greco FA; Stein RS; Cousar JB; Flexner JM; Hainsworth JD
Cancer; 1991 Jul; 68(2):233-41. PubMed ID: 1712662
[TBL] [Abstract][Full Text] [Related]
13. The management of locally advanced breast cancer: a combined modality approach.
Kantarjian HM; Hortobagyi GN; Smith TL; Blumenschein GR; Montague E; Buzdar AU; Martin RG
Eur J Cancer Clin Oncol; 1984 Nov; 20(11):1353-61. PubMed ID: 6548710
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy in locally advanced breast cancer.
Singh G; Singh DP; Gupta D; Muralikrishna BV
J Surg Oncol; 1996 Jan; 61(1):38-41. PubMed ID: 8544458
[TBL] [Abstract][Full Text] [Related]
15. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
Longo DL; DeVita VT; Duffey PL; Wesley MN; Ihde DC; Hubbard SM; Gilliom M; Jaffe ES; Cossman J; Fisher RI
J Clin Oncol; 1991 Jan; 9(1):25-38. PubMed ID: 1702144
[TBL] [Abstract][Full Text] [Related]
16. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study.
Rivkin SE; Green S; Metch B; Glucksberg H; Gad-el-Mawla N; Constanzi JJ; Hoogstraten B; Athens J; Maloney T; Osborne CK
J Clin Oncol; 1989 Sep; 7(9):1229-38. PubMed ID: 2671283
[TBL] [Abstract][Full Text] [Related]
18. High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team.
Somlo G; Doroshow JH; Forman SJ; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Akman SA; Ahn C; Nagasawa S
Cancer; 1994 Mar; 73(6):1678-85. PubMed ID: 7512436
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer.
Vokes EE; Schilsky RL; Weichselbaum RR; Guaspari A; Guarnieri CM; Whaling SM; Panje WR
Cancer; 1989 Mar; 63(6 Suppl):1048-53. PubMed ID: 2783881
[TBL] [Abstract][Full Text] [Related]
20. Intraarterial induction chemotherapy in locally advanced stage III breast cancer.
Stephens FO
Cancer; 1990 Aug; 66(4):645-50. PubMed ID: 2386893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
